Teva Pharmaceutical Industries Limited Ordinary Shares
TEVA · NYSE
Analyst Consensus
Analyst Ratings Synthesis
The supplied consensus is Buy, backed by 12 analysts, with a mean price target of $42.50. The low and high targets are not available, so the target range and degree of dispersion cannot be established from the figures provided. No most- or least-bullish analyst or firm is identified. The evidence reports no analyst rating or target revisions during the past week, so there is no supported direction of revisions to describe. The substantive disagreement visible in the supplied material is about valuation: GuruFocus flags TEVA as 134.2% overvalued on its GF Value measure, while a Simply Wall St article asks whether the shares are undervalued after new Phase 3 schizophrenia data. No analyst-specific target spread is supplied to explain the difference.
- Teva's Branded Drugs Take Center Stage in Its Growth Strategy
- Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround
- Teva Pharma Secures FDA Nod For DEGEVMA, A Biosimilar To Xgeva
- iShares Core MSCI EAFE ETF Experiences Big Inflow
- LAIs in Schizophrenia: Teva Resource Promotes Earlier Use
